Drugs.com - New Drug Approvals

FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia

INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Ospomyv (denosumab-dssb; SB16; 60 mg pre-filled syringe)...

Feb 17, 2025 - 07:28
 0
FDA Approves Ospomyv (denosumab-dssb), a Biosimilar to Prolia
INCHEON, Korea – Feb 16, 2025 – Samsung Bioepis Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Ospomyv (denosumab-dssb; SB16; 60 mg pre-filled syringe)...
Read More

Tags:

Previous Article

Allergan Aesthetics Introduces New AMI Training Centers Across the US

Next Article

UAE expands Visa-on-Arrival for Indian Nationals

Related Posts

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections

FDA Approves Emblaveo (aztreonam and avibactam) for the...

Feb 10, 2025  0

Enhertu Approved as First HER2-Directed Therapy for Patients with HER2-Low or HER2-Ultralow Metastatic Breast Cancer

Enhertu Approved as First HER2-Directed Therapy for Pat...

Feb 9, 2025  0

FDA Approves Emblaveo (aztreonam and avibactam) for the Treatment of Adults With Complicated Intra-Abdominal Infections With Limited or No Treatment Options

FDA Approves Emblaveo (aztreonam and avibactam) for the...

Feb 10, 2025  0